Physician profile
Daesoon Leem
NPI 1902289226
$2,876.97
in general payments reported to CMS, 2019-2025
29 companies · $183 in 2025
The $183 reported for 2025 was more than what a typical Sports Medicine (Family Medicine) provider received nationally (typical 2025 total: $113).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $119 · 2022: $986 · 2023: $1,238 · 2024: $351 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,760 · Travel and Lodging: $11.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,760.32 |
| Travel and Lodging | $11.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Bayer Healthcare Pharmaceuticals INC. | $470.75 | 2022-2023 | |
| Abbvie INC. | $251.98 | 2022-2023 | |
| Lilly USA, LLC | $167.31 | 2023 | Jardiance, Mounjaro |
| Nestle Healthcare Nutrition INC. | $146.98 | 2023 | |
| Glaxosmithkline, LLC. | $146.37 | 2023-2024 | Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $138.36 | 2022-2023 | Farxiga |
| Novo Nordisk INC | $136.24 | 2022-2025 | |
| Halozyme INC | $127.39 | 2023 | |
| Amgen INC. | $126.32 | 2023-2025 | Repatha, Repatha, Otezla |
| Regeneron Healthcare Solutions, INC. | $118.26 | 2022 | |
| Eisai INC. | $113.12 | 2024 | |
| Radius Health, INC. | $101.48 | 2022 | |
| Solta Medical, A Division of Bausch Health US, LLC | $86.37 | 2024 | |
| Bioventus LLC | $76.51 | 2019-2025 | Xcell |
| Boehringer Ingelheim Pharmaceuticals, INC. | $75.79 | 2023-2024 | Jardiance |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alexion Pharmaceuticals, INC. | $73.07 | 2023-2025 | Strensiq |
| Ibsa Pharma INC. | $68.05 | 2023 | Licart |
| Dexcom, INC. | $66.91 | 2022 | |
| Pacira Therapeutics, INC. | $61.23 | 2019 | |
| Abiomed | $57.65 | 2023 | Impella |
| Ironwood Pharmaceuticals, INC | $55.57 | 2023-2024 | Linzess |
| Revance Therapeutics, INC. | $50.22 | 2024-2025 | Daxxify |
| Samsung Hme America, INC. | $30.00 | 2019 | |
| Sumitomo Pharma America, INC. | $26.72 | 2025 | Gemtesa |
| Zimmer Biomet Holdings, INC. | $21.89 | 2024 | Gel-One Cross-Linked Hyaluronate |
| Medline Industries LP | $21.56 | 2025 | |
| Aimmune Therapeutics, INC. | $21.14 | 2024 | |
| Novartis Pharmaceuticals Corporation | $20.80 | 2022 | |
| Gilead Sciences, INC. | $18.93 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Daesoon Leem listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.